As of 2025-03-15, the EV/EBITDA ratio of Apellis Pharmaceuticals Inc (APLS) is -18.75. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Apellis's latest enterprise value is 3,100.46 mil USD. Apellis's TTM EBITDA according to its financial statements is -165.35 mil USD. Dividing these 2 quantities gives us the above Apellis EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 10.9x - 13.5x | 12.6x |
| Forward P/E multiples | 17.4x - 34.9x | 21.6x |
| Fair Price | (23.25) - (18.14) | (22.86) |
| Upside | -195.4% - -174.4% | -193.8% |
| Date | EV/EBITDA |
| 2025-03-12 | -19.37 |
| 2025-03-11 | -19.62 |
| 2025-03-10 | -19.34 |
| 2025-03-07 | -19.26 |
| 2025-03-06 | -19.47 |
| 2025-03-05 | -19.99 |
| 2025-03-04 | -19.27 |
| 2025-03-03 | -18.52 |
| 2025-02-28 | -19.34 |
| 2025-02-27 | -19.99 |
| 2025-02-26 | -20.24 |
| 2025-02-25 | -20.67 |
| 2025-02-24 | -21.06 |
| 2025-02-21 | -21.14 |
| 2025-02-20 | -21.77 |
| 2025-02-19 | -21.80 |
| 2025-02-18 | -21.64 |
| 2025-02-14 | -21.05 |
| 2025-02-13 | -21.10 |
| 2025-02-12 | -21.89 |
| 2025-02-11 | -21.91 |
| 2025-02-10 | -22.02 |
| 2025-02-07 | -22.56 |
| 2025-02-06 | -23.18 |
| 2025-02-05 | -23.31 |
| 2025-02-04 | -22.10 |
| 2025-02-03 | -21.88 |
| 2025-01-31 | -22.27 |
| 2025-01-30 | -23.32 |
| 2025-01-29 | -22.62 |
| 2025-01-28 | -22.48 |
| 2025-01-27 | -22.87 |
| 2025-01-24 | -23.02 |
| 2025-01-23 | -23.60 |
| 2025-01-22 | -23.32 |
| 2025-01-21 | -23.12 |
| 2025-01-17 | -22.98 |
| 2025-01-16 | -22.82 |
| 2025-01-15 | -22.29 |
| 2025-01-14 | -21.27 |
| 2025-01-13 | -21.95 |
| 2025-01-10 | -21.08 |
| 2025-01-08 | -25.30 |
| 2025-01-07 | -26.54 |
| 2025-01-06 | -26.35 |
| 2025-01-03 | -25.65 |
| 2025-01-02 | -25.42 |
| 2024-12-31 | -24.47 |
| 2024-12-30 | -24.47 |
| 2024-12-27 | -25.06 |